Baseline characteristics
death, head of pancreas primary tumor
ONCOLOGY
From March 2016 to October 2019, 24 patients were screened, but four were ineligible and one withdrew consent during screening. Nineteen patients were enrolled; they were all followed until death or data cutoff date, June 1, 2021. Despite meeting the interim standard to continue to second stage of the trial, the study ended early following a multidisciplinary review at OHSU and discussion with the sponsor in consideration of other ongoing national neoadjuvant trials, which would impact timely accrual. Among the 19 patients, the median age was 68 (range 42–76). The majority had Eastern Cooperative Oncology Group performance status 1, head of pancreas primary tumor, involvement of both arterial and venous vasculature, clinically positive nodes, and abnormally elevated CA19‐9 at baseline (Table Baseline characteristics.Median (range).